MRC Confidence in Concept Fund

MRC Confidence in Concept Fund

The Tropical Infectious Disease Consortium (TIDC) has been awarded £1.6 million from the Medical Research Council (MRC) via the Impact Acceleration Account (IAA), previously Confidence in Concept (CiC). The TIDC is a strategic partnership between Liverpool School of Tropical Medicine (LSTM), UK Health Security Agency, London School of Hygiene & Tropical Medicine (LSHTM), the University of Oxford and has been expanded for this call to include the Science and Technology Facilities Council (STFC) and the Pirbright Institute. The TIDC has been awarded £1.6million over 3 years and represents the largest award to date.  The award will allow the Consortium to support pump-priming projects, typically in the range of £50K, with the overreaching ambition to accelerate the transition from discovery science into therapeutic, diagnostic and vaccine development.

 

 
 

The Tropical Infectious Disease Consortium (TIDC) has been awarded £1.6 million from the Medical Research Council (MRC) via the Impact Acceleration Account (IAA), previously Confidence in Concept (CiC). The TIDC is a strategic partnership between Liverpool School of Tropical Medicine (LSTM), UK Health Security Agency, London School of Hygiene & Tropical Medicine (LSHTM), the University of Oxford and has been expanded for this call to include the Science and Technology Facilities Council (STFC) and the Pirbright Institute. The TIDC has been awarded £1.6million over 3years and represents the largest award to date. The award will allow the Consortium to support pump-priming projects, typically in the range of £50K, with the overreaching ambition to accelerate the transition from discovery science into therapeutic, diagnostic and vaccine development.

Professor Giancarlo Biagini is Head of LSTM’s Department of Tropical Disease Biology and Co-I within the Consortium. He said: “We are delighted to be able to widen the partnership within the TIDC, which was established in 2013 and has been successful in every round of this call to date. Since 2013 we have received more than £4 million in funding, have been able to leverage in the region of £60 million, supported 100 projects and facilitated 136 industry interactions. This latest award represents more investment in ideas that can increase tangible outputs that demonstrate impact within a wide range of areas.”

Projects within the following categories will be eligible to apply:

• Diagnostics
• Therapeutics
• Vaccines
• Vector control tools
• Translational focussed Informatics
• Translational enabling technologies

Eligible projects should be at the stage where allocated funding by the Consortium would develop the approach to the next level where it would be capable of successfully applying to larger external translational funding sources. It is the objective of the Tropical Infectious Disease Consortium to create a critical mass necessary for UK researchers who are interested in translating their research into health benefits, which will support them in an increasingly competitive international market. The aim is to support a high number of scientifically excellent translational proposals.

Applications are required to have a Principal Investigator from one of the Consortium’s partner institutions. The PI can be from any academic department and would typically be an academic and research active member of staff that meets the following criteria:

• Contract duration longer than CiC project
• MIN 4years PDRA experience
• Previous experience/evidence in securing funding OR in research project leadership role (evidence required in application form)

PIs can submit multiple applications but only their top scoring project will be funded.
Applications that involve collaboration between more than one partner institution are encouraged.
A weighting will be added to the GPA if the project involves collaborations with SMEs/Pharma, but these must be led by an eligible academic PI.